227 related articles for article (PubMed ID: 19304895)
1. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses.
Li M; Liu X; Zhou Y; Su SB
J Leukoc Biol; 2009 Jul; 86(1):23-32. PubMed ID: 19304895
[TBL] [Abstract][Full Text] [Related]
2. Type III Interferons in Viral Infection and Antiviral Immunity.
Zhou JH; Wang YN; Chang QY; Ma P; Hu Y; Cao X
Cell Physiol Biochem; 2018; 51(1):173-185. PubMed ID: 30439714
[TBL] [Abstract][Full Text] [Related]
3. IFN-λs.
Kotenko SV
Curr Opin Immunol; 2011 Oct; 23(5):583-90. PubMed ID: 21840693
[TBL] [Abstract][Full Text] [Related]
4. Novel type III interferons produce anti-tumor effects through multiple functions.
Li Q; Kawamura K; Tada Y; Shimada H; Hiroshima K; Tagawa M
Front Biosci (Landmark Ed); 2013 Jun; 18(3):909-18. PubMed ID: 23747856
[TBL] [Abstract][Full Text] [Related]
5. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.
Kotenko SV; Gallagher G; Baurin VV; Lewis-Antes A; Shen M; Shah NK; Langer JA; Sheikh F; Dickensheets H; Donnelly RP
Nat Immunol; 2003 Jan; 4(1):69-77. PubMed ID: 12483210
[TBL] [Abstract][Full Text] [Related]
6. Biological activity of interleukins-28 and -29: comparison with type I interferons.
Meager A; Visvalingam K; Dilger P; Bryan D; Wadhwa M
Cytokine; 2005 Jul; 31(2):109-18. PubMed ID: 15899585
[TBL] [Abstract][Full Text] [Related]
7. SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29.
Brand S; Zitzmann K; Dambacher J; Beigel F; Olszak T; Vlotides G; Eichhorst ST; Göke B; Diepolder H; Auernhammer CJ
Biochem Biophys Res Commun; 2005 Jun; 331(2):543-8. PubMed ID: 15850793
[TBL] [Abstract][Full Text] [Related]
8. Interferon-lambda: a new addition to an old family.
Donnelly RP; Kotenko SV
J Interferon Cytokine Res; 2010 Aug; 30(8):555-64. PubMed ID: 20712453
[TBL] [Abstract][Full Text] [Related]
9. Induction of an antiviral state and attenuated coxsackievirus replication in type III interferon-treated primary human pancreatic islets.
Lind K; Richardson SJ; Leete P; Morgan NG; Korsgren O; Flodström-Tullberg M
J Virol; 2013 Jul; 87(13):7646-54. PubMed ID: 23637411
[TBL] [Abstract][Full Text] [Related]
10. [Action of type III IFNs and their roles in immune responses].
Domagalski K; Tretyn A; Pawłowska M; Szczepanek J; Halota W
Postepy Hig Med Dosw (Online); 2010 Oct; 64():522-33. PubMed ID: 21109705
[TBL] [Abstract][Full Text] [Related]
11. Type III interferons (IFNs): Emerging Master Regulators of Immunity.
Galani IE; Koltsida O; Andreakos E
Adv Exp Med Biol; 2015; 850():1-15. PubMed ID: 26324342
[TBL] [Abstract][Full Text] [Related]
12. Viral infections activate types I and III interferon genes through a common mechanism.
Onoguchi K; Yoneyama M; Takemura A; Akira S; Taniguchi T; Namiki H; Fujita T
J Biol Chem; 2007 Mar; 282(10):7576-81. PubMed ID: 17204473
[TBL] [Abstract][Full Text] [Related]
13. Integrative genomic analyses on interferon-lambdas and their roles in cancer prediction.
Yang L; Wei J; He S
Int J Mol Med; 2010 Feb; 25(2):299-304. PubMed ID: 20043142
[TBL] [Abstract][Full Text] [Related]
14. Expression of type III interferons (IFNλs) and their receptor in Sjögren's syndrome.
Apostolou E; Kapsogeorgou EK; Konsta OD; Giotakis I; Saridaki MI; Andreakos E; Tzioufas AG
Clin Exp Immunol; 2016 Dec; 186(3):304-312. PubMed ID: 27613139
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antiviral activity of lambda-interferons against HIV replication in macrophages.
Wang Y; Li J; Wang X; Zhou Y; Zhang T; Ho W
J Interferon Cytokine Res; 2015 Mar; 35(3):213-21. PubMed ID: 25268605
[TBL] [Abstract][Full Text] [Related]
16. IL-28, IL-29 and their class II cytokine receptor IL-28R.
Sheppard P; Kindsvogel W; Xu W; Henderson K; Schlutsmeyer S; Whitmore TE; Kuestner R; Garrigues U; Birks C; Roraback J; Ostrander C; Dong D; Shin J; Presnell S; Fox B; Haldeman B; Cooper E; Taft D; Gilbert T; Grant FJ; Tackett M; Krivan W; McKnight G; Clegg C; Foster D; Klucher KM
Nat Immunol; 2003 Jan; 4(1):63-8. PubMed ID: 12469119
[TBL] [Abstract][Full Text] [Related]
17. Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus.
Yoshio S; Kanto T; Kuroda S; Matsubara T; Higashitani K; Kakita N; Ishida H; Hiramatsu N; Nagano H; Sugiyama M; Murata K; Fukuhara T; Matsuura Y; Hayashi N; Mizokami M; Takehara T
Hepatology; 2013 May; 57(5):1705-15. PubMed ID: 23213063
[TBL] [Abstract][Full Text] [Related]
18. Human interferon-lambda3 is a potent member of the type III interferon family.
Dellgren C; Gad HH; Hamming OJ; Melchjorsen J; Hartmann R
Genes Immun; 2009 Mar; 10(2):125-31. PubMed ID: 18987645
[TBL] [Abstract][Full Text] [Related]
19. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression.
Brand S; Beigel F; Olszak T; Zitzmann K; Eichhorst ST; Otte JM; Diebold J; Diepolder H; Adler B; Auernhammer CJ; Göke B; Dambacher J
Am J Physiol Gastrointest Liver Physiol; 2005 Nov; 289(5):G960-8. PubMed ID: 16051921
[TBL] [Abstract][Full Text] [Related]
20. Potential anti-tumor effect of IFN-λ2 (IL-28A) against human lung cancer cells.
Tezuka Y; Endo S; Matsui A; Sato A; Saito K; Semba K; Takahashi M; Murakami T
Lung Cancer; 2012 Dec; 78(3):185-92. PubMed ID: 23021208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
